{
  "context": {
    "rules": [
      "Rule1: If the FDA reviews the application from the pharmaceutical platform, then should the drug fail to meet standards set by legislation, the FDA does not grant marketing authorization for the drug.",
      "Rule2: Either the FDA reviews the application from the pharmaceutical platform or the FDA evaluates data from the pharmaceutical platform.",
      "Rule3: Either the FDA fast-tracks approval for the drug, or if it is not the case that the FDA evaluating data from the pharmaceutical platform leads to the outcome that when the drug fails to meet standards set by legislation the FDA does not grant marketing authorization for the drug, then the FDA does not request additional studies from the pharmaceutical platform.",
      "Rule4: Either the FDA imposes restrictions on the drug or the drug meets standards set by legislation.",
      "Rule5: Either the FDA lifts restrictions on the drug or the FDA does not impose restrictions on the drug.",
      "Rule6: If the FDA conducts a safety review of the drug, then should the drug not meet standards set by legislation, the FDA requires labeling changes for the drug.",
      "Rule7: Either the FDA conducts a safety review of the drug or the FDA performs a risk assessment of the drug.",
      "Rule8: If the FDA performs a risk assessment of the drug, then provided that the drug does not meet standards set by legislation, the FDA requires labeling changes for the drug.",
      "Rule9: If the pharmaceutical platform identifies contraindications for the drug, then the pharmaceutical platform updates the safety profile of the drug.",
      "Rule10: Either the pharmaceutical platform identifies contraindications for the drug or the pharmaceutical platform discovers side effects of the drug.",
      "Rule11: If the pharmaceutical platform conducts clinical trials for the drug, then should the pharmaceutical platform receive approval from the FDA, the drug meets standards set by legislation.",
      "Rule12: If the pharmaceutical platform discovers side effects of the drug, then under the condition that the drug does not meet standards set by legislation, the FDA does not grant marketing authorization for the drug.",
      "Rule13: Either the pharmaceutical platform appeals the decision with the FDA, or if the pharmaceutical platform updates the safety profile of the drug, then when the drug does not meet standards set by legislation, the FDA does not grant marketing authorization for the drug.",
      "Rule14: If the pharmaceutical platform implements quality controls for the drug, then the pharmaceutical platform modifies the manufacturing process for the drug.",
      "Rule15: Either the pharmaceutical platform implements quality controls for the drug or the pharmaceutical platform changes production methods for the drug.",
      "Rule16: If the pharmaceutical platform violates regulations with the FDA, then the pharmaceutical platform faces penalties from the FDA.",
      "Rule17: If the pharmaceutical platform violates regulations with the FDA, then the pharmaceutical platform does not face penalties from the FDA.",
      "Rule18: Either the pharmaceutical platform violates regulations with the FDA, or if the pharmaceutical platform changes production methods for the drug, then the FDA does not impose restrictions on the drug.",
      "Rule19: If the pharmaceutical platform submits data to the FDA, then provided that the pharmaceutical platform receives approval from the FDA, the drug meets standards set by legislation.",
      "Rule20: Either the pharmaceutical platform completes research on the drug or the pharmaceutical platform provides evidence to the FDA.",
      "Rule21: If the pharmaceutical platform provides evidence to the FDA, then the pharmaceutical platform submits data to the FDA.",
      "Rule22: If the FDA initiates an audit of the pharmaceutical platform, then the FDA issues a warning to the pharmaceutical platform.",
      "Rule23: If the FDA issues a warning to the pharmaceutical platform, then the FDA finds regulatory violations by the pharmaceutical platform.",
      "Rule24: If it is not the case that the FDA evaluating data from the pharmaceutical platform leads to the outcome that when the drug fails to meet standards set by legislation the FDA does not grant marketing authorization for the drug, then the FDA requests additional studies from the pharmaceutical platform.",
      "Rule25: If it is not the case that the pharmaceutical platform completing research on the drug leads to the pharmaceutical platform conducting clinical trials for the drug, then the FDA initiates an audit of the pharmaceutical platform.",
      "Rule26: If the drug does not meet standards set by legislation, then the FDA grants marketing authorization for the drug.",
      "Rule27: If the drug does not meet standards set by legislation, then the FDA does not require labeling changes for the drug."
    ],
    "facts": [
      "Fact1: The pharmaceutical platform receives approval from the FDA.",
      "Fact2: The FDA does not fast-track approval for the drug.",
      "Fact3: The FDA does not lift restrictions on the drug.",
      "Fact4: The pharmaceutical platform does not appeal the decision with the FDA.",
      "Fact5: The pharmaceutical platform does not modify the manufacturing process for the drug.",
      "Fact6: The FDA does not find regulatory violations by the pharmaceutical platform."
    ]
  },
  "question": "The drug meets standards set by legislation."
}